The global Lewy body dementia market size is expected to be worth USD 1.35 Billion in 2025. It can surge to a valuation of USD 2.27 Billion by 2032. The market is anticipated to exhibit a CAGR of 7.7% during the forecast period (2025-2032).  

Government initiatives created for the awareness of Lewy body dementia (LBD) and investments made for dementia care centers can drive the market growth. The effort made by pharmaceutical companies to develop biomarkers and other tests for accurate diagnosis can further contribute to the market growth.

However, the lack of symptomatic treatment that permanently stalls the progression of Lewy body dementia can impede the market growth.

Key Market Insights

The Lewy body dementia market is expected to scale owing to the rising cases of progressive dementia and the use of biomarkers for effective diagnosis.

• By diagnosis, the biomarker-based diagnosis segment is expected to score 40.8% share in 2025. The use of blood biomarkers for the early detection of dementia can fuel the segment’s growth over the forecast period.
• By medication, the antipsychotics segment is anticipated to attain 17% market share in 2025. This is on account of these drugs controlling the behavior of patients and improving their mood. However, their side effects can negatively impact the segment’s growth.
• By end user, the long-term care facilities segment is expected to capture 21% share of the Lewy body dementia market in 2025. The segment’s growth is expected to be gradual in the market, owing to dementia affecting the elderly and the positive effects of long-term care.
• By region, Asia Pacific is projected to capture a significant market share in 2025 owing to the interest in neurodegenerative disease treatments and the utilization of 123I-MIBG Myocardial Scintigraphy for the detection of dysfunction of motor functions. Improvements in healthcare infrastructure in India and China can contribute to the regional market growth.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/lewy-body-dementia-market

Lewy Body Dementia Market Report Coverage

Market Dynamics

The demand for definitive diagnostics to detect Lewy body dementia can drive the market growth. LBD covers Parkinson’s and dementia with Lewy bodies. The large rate of misdiagnosis despite having access to patient medical history, neurological examinations, and imaging tests is enabling the driver. The potential of novel diagnostic tests for the detection of alpha-synuclein can bode well for the market. For instance, the Syn-One Test by CND Lifesciences can accurately detect phosphorylated alpha-synuclein (P-SYN). The skin-based biopsy allows doctors to differentiate between disorders with similar symptoms.

Partnerships formed for funding clinical studies of dementia can shape the market growth. These partnerships aim to fuel the development of disease-modifying drugs for Lewy body dementia and other forms of dementia. The Accelerating Medicines Partnership in Parkinson’s Disease and Related Disorders (AMP PDRD), a public-private partnership established on July 17, 2024, is one such instance. It is expected to work in tandem with resources from various esteemed organizations and heavy capital to advance research and improve patient outcomes.

Market Opportunity: Biomarkers for Early Detection of LBD

Blood biomarkers can allow for the early diagnosis of LBD and enable targeted therapies. The detection of acetyl-L-carnitine (LAC) and free carnitine levels can allow clinicians to detect the disorder accurately. The research was published in Molecular Psychiatry on January 07, 2025, which identified the low levels of LAC caused dementia in men, while women had dementia with declining levels of LAC and free carnitine. This breakthrough can lead the way for a blood test that accurately monitors these compounds for the detection of early dementia in men and women.

Market Challenge: Complex Symptom Management of LBD

The management of LBD requires a team of specialists, which can be expensive for the average patient. It is challenging owing to motor impairment and cognitive dysfunction, a combination of pharmacological therapies and personalized care.

Analyst’s View

• The prevalence of dementia and the demand for early diagnosis are the main drivers of the Lewy body dementia market.
• The biomarker-based diagnosis is expected to capture a significant market share in 2025 due to its accuracy in the early detection of neurodegenerative disorders.
• Key players are likely to focus on biomarker-based therapies to gain access to revenue streams.

Recent Developments

IGC Pharma announced an upgrade to its AI platform, Multimodal Interpretable Transformer for Alzheimer’s (MINT-AD), for the early detection of dementia and Alzheimer’s, and dementia with Lewy bodies (DLB) on March 04, 2025. The platform is trained on clinical data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), the National Alzheimer's Coordinating Center (NACC), and others.

Competitor Insights

• Sun Pharma Advanced Research Company Limited
• CuraSen Therapeutics, Inc.
• Eli Lilly and Company
• Athira Pharma
• Eisai Inc.
• EIP Pharma Inc.
• Aptinyx
• Cognition Therapeutics

Market Segmentation

• By Diagnosis
• Clinical Diagnosis
• Biomarker-based Diagnosis
• By Medication
• Cholinesterase Inhibitors
• Antipsychotics
• Antidepressants
• Others (e.g., Parkinson’s medications, etc.)
• By End User
• Hospitals
• Specialty Clinics
• Long-term Facilities
• Others

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • Russia
  • France
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • China
  • Japan
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa